相关实验视频
Updated: Sep 9, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
348
从更好的诊断到早期治疗:阿尔茨海默病的快速发展
Anastasia Bougea1, Manuel Debasa-Mouce2, Shelly Gulkarov3
1Medical School, National and Kapodistrian University of Athens, 10679 Athens, Greece.
Medicina (Kaunas, Lithuania)
|August 28, 2025
概括
生物标志物显著改善了阿尔茨海默病 (AD) 的诊断,但粉样蛋白假设面临挑战. 新型疗法和药物输送系统对未来的阿尔茨海默病治疗有希望.
科学领域:
- 神经科学
- 生物化学
- 遗传学
背景情况:
- 阿尔茨海默病的研究正在转向早期检测和干预.
- 关键领域包括生物标志物,神经心理测试,分子机制和治疗方法.
研究的目的:
- 审查生物标志物在阿尔茨海默病诊断中的作用.
- 检查AD生物标志物的神经心理测试.
- 讨论粉样蛋白假设和AD分子机制.
- 探索创新的AD治疗方法和研究挑战.
主要方法:
- 在PubMed和Scopus上搜索英语研究文章.
- 包括关于AD机制,生物标志物和治疗方法的临床前,临床研究,评论和元分析.
主要成果:
- 通过全基因组关联研究 (GWAS) 确定了AD风险位点.
- 核心生物标志物 (Aβ42,tau,粉体PET) 检测早期的AD;核心2生物标志物预测进展.
- 针对粉样蛋白的疗法已经面临失败, 质疑粉样蛋白级联假设.
- 阿尔茨海默病的机制包括粉样蛋白/陶蛋白,神经炎症,氧化应激和脂质失调.
- 先进的药物输送系统旨在克服血脑屏障 (BBB).
- 单克隆抗体 (Aducanumab,Lecanemab) 和BACE抑制剂显示出治疗潜力.
- 基因疗法 (CRISPR/Cas9用于APOE) 提供了新的途径.
结论:
- 神经退行性生物标志物提高了阿尔茨海默病的诊断准确性.
- 粉样蛋白假设需要进一步调查.
- 新的单克隆抗体可能会减缓阿尔茨海默病的进展.
- 改善BBB药物输送系统对于有效的AD治疗至关重要.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.4K
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
13.5K
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702